Canadian scientist Dr. Pieter Cullis, together with his peers Drs Katalin Kariko and Drew Weissman, have been honoured with the 2021 Prince Mahidol Award for their contributions to the development of COVID-19 messenger RNA (mRNA) vaccines. Through over 40 years of work in his University of British Columbia (UBC) laboratory,… Read More »Canadian scientist awarded international prize for COVID vaccine technology
https://youtu.be/AuEkO4Ge-q4 Thomas Madden (Acuitas) interviewed on Global TV Acuitas Therapeutics, the Vancouver, BC-based biotech company co-founded by NMIN research leader Dr. Pieter Cullis, has been granted a Global Impact Award by Life Sciences British Columbia, in recognition of the company’s “extraordinary leadership and efforts they made in the development of… Read More »Acuitas Therapeutics wins Global Impact Award for LNPs in COVID vaccines
“There is no time like the present to try to achieve impossible dreams” The contributions of NMIN Research Leader Dr. Pieter Cullis toward enabling effective mRNA vaccines, most notably against COVID-19, continue to garner high-profile recognition. Most recently, Dr. Cullis was featured on CBC’s Quirks & Quarks; his role was… Read More »LNPs & mRNA vaccines: Dr. Pieter Cullis in Nature Reviews Materials
NMIN’s Scientific Director Dr. Christine Allen has named Dr. Warren Chan the new co-leader of NMIN’s Theme III: Diagnostics research team. “I’m delighted that Dr. Chan has agreed to take on this role,” comments Dr. Allen. “He is a world renowned expert in diagnostics and an excellent role model for… Read More »Dr. Warren Chan named co-leader of NMIN’s Diagnostics Theme
NMIN is collaborating with its partner organization NanoCanada to build a Canadian Nanomedicine Cluster that will offer a hub for collaboration and partnerships, provide a database of expertise and capabilities, and showcase Canada’s leadership on the global stage. As part of this collaboration, NMIN Executive Director Dr. Diana Royce has… Read More »NMIN supports NanoCanada’s Canadian Nanomedicine Cluster initiative
NMIN submitted its second Annual Progress Report to the NCE on 15 June 2021. The report compiled the network’s progress as of the end of 2020-21, accomplished despite the challenges associated with the COVID-19 pandemic. Among the achievements reported: NMIN has made 32 research investments, including 24 research projects, 2… Read More »NMIN’s Annual Progress Report compiles 2020-21 achievements
The NanoMedicines Innovation Network (NMIN) is pleased to introduce the 2021-22 Executive Committee of its Highly Qualified Personnel (HQP) Network – the NMIN HQP Network (NHN). The NHN Executive Committee is comprised entirely of NMIN HQP, and plays a leadership role in the planning and realization of NMIN’s HQP programs,… Read More »Announcing the 2021-22 NMIN HQP Network Leadership Team
Top L to R: Brenna Rauw, Stephen Dibert, Inès Holzbaur, Wendy Lamson. Bottom L to R: Lihn Le, Helen Loughrey, Paul Santerre, Andrew Sinclair, Gary Skarja. The NanoMedicines Innovation Network (NMIN) is pleased to introduce the inaugural members of its Commercialization Advisory Board (CAB). The Commercialization Advisory Board (CAB) provides… Read More »Meet NMIN’s Commercialization Advisory Board (CAB)
The NanoMedicines Innovation Network (NMIN), a national research network funded by the Government of Canada, has appointed Dr. Christine Allen Scientific Director & CEO, effective 1 July 2021. Dr. Allen is Associate Vice-President and Vice-Provost, Strategic Initiatives, and Professor in the Leslie Dan Faculty of Pharmacy, at the University of… Read More »NMIN names new Scientific Director & CEO Dr. Christine Allen
Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November 2020, growing recognition has been given to the Canadian nanomedicine-based component underlying the vaccine’s effectiveness: the lipid nanoparticle (LNP) delivery system that originated from basic research by NMIN Scientific Director Dr. Pieter Cullis that started over 40 years ago… Read More »Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines